Cognition Therapeutics, Inc. (CGTX)

Last Closing Price: 2.07 (2023-05-26)

Company Description

Cognition Therapeutics a clinical-stage biopharmaceutical company. It engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Cognition Therapeutics based in PURCHASE, N.Y.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-21.40M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 1.69
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -59.61%
Return on Assets (Trailing 12 Months) -46.89%
Current Ratio (Most Recent Fiscal Quarter) 5.73
Quick Ratio (Most Recent Fiscal Quarter) 5.73
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $1.39
Earnings per Share (Most Recent Fiscal Quarter) $-0.21
Earnings per Share (Most Recent Fiscal Year) $-0.91
Diluted Earnings per Share (Trailing 12 Months) $-0.95
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 29.28M
Free Float 23.26M
Market Capitalization $60.60M
Average Volume (Last 20 Days) 0.11M
Beta (Past 60 Months) 1.64
Percentage Held By Insiders (Latest Annual Proxy Report) 20.55%
Percentage Held By Institutions (Latest 13F Reports) 23.06%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%